Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160)

N.R. Hill; D. Lasserson; B. Thompson; R. Perera-Salazar; J. Wolstenholme; P. Bower; T. Blakeman; D. Fitzmaurice; P. Little; G. Feder; N. Qureshi; M. Taal; J. Townend; C. Ferro; R. McManus; F.D.R. Hobbs

doi:10.1186/s13063-022-06972-9

Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160)

N.R. Hill, D. Lasserson, B. Thompson, R. Perera-Salazar, J. Wolstenholme, P. Bower, T. Blakeman, D. Fitzmaurice, P. Little, G. Feder, N. Qureshi, M. Taal, J. Townend, C. Ferro, R. McManus, F.D.R. Hobbs

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	Trials
DOIs	https://doi.org/10.1186/s13063-022-06972-9
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13063-022-06972-9

Cite this

Hill, N. R., Lasserson, D., Thompson, B., Perera-Salazar, R., Wolstenholme, J., Bower, P., Blakeman, T., Fitzmaurice, D., Little, P., Feder, G., Qureshi, N., Taal, M., Townend, J., Ferro, C., McManus, R., & Hobbs, F. D. R. (2022). Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160). Trials. https://doi.org/10.1186/s13063-022-06972-9

Hill, N.R. ; Lasserson, D. ; Thompson, B. et al. / Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160). In: Trials. 2022.

@article{1f96513a8fde404c8e0d87995a832b67,

title = "Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160)",

author = "N.R. Hill and D. Lasserson and B. Thompson and R. Perera-Salazar and J. Wolstenholme and P. Bower and T. Blakeman and D. Fitzmaurice and P. Little and G. Feder and N. Qureshi and M. Taal and J. Townend and C. Ferro and R. McManus and F.D.R. Hobbs",

year = "2022",

doi = "10.1186/s13063-022-06972-9",

language = "Undefined",

journal = "Trials",

issn = "1745-6215",

publisher = "Springer Nature",

}

Hill, NR, Lasserson, D, Thompson, B, Perera-Salazar, R, Wolstenholme, J, Bower, P , Blakeman, T, Fitzmaurice, D, Little, P, Feder, G, Qureshi, N, Taal, M, Townend, J, Ferro, C, McManus, R & Hobbs, FDR 2022, 'Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160)', Trials. https://doi.org/10.1186/s13063-022-06972-9

Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160). / Hill, N.R.; Lasserson, D.; Thompson, B. et al.
In: Trials, 2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160)

AU - Hill, N.R.

AU - Lasserson, D.

AU - Thompson, B.

AU - Perera-Salazar, R.

AU - Wolstenholme, J.

AU - Bower, P.

AU - Blakeman, T.

AU - Fitzmaurice, D.

AU - Little, P.

AU - Feder, G.

AU - Qureshi, N.

AU - Taal, M.

AU - Townend, J.

AU - Ferro, C.

AU - McManus, R.

AU - Hobbs, F.D.R.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85143676857&partnerID=MN8TOARS

U2 - 10.1186/s13063-022-06972-9

DO - 10.1186/s13063-022-06972-9

M3 - Article

SN - 1745-6215

JO - Trials

JF - Trials

ER -

Hill NR, Lasserson D, Thompson B, Perera-Salazar R, Wolstenholme J, Bower P et al. Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160). Trials. 2022. doi: 10.1186/s13063-022-06972-9

UN SDGs

Access to Document

Other files and links

Cite this